Zynerba Pharmaceuticals Inc represents values of innovation, patient-centricity, and scientific excellence. The company's corporate philosophy revolves around developing and commercializing innovative therapeutics for patients with severe and rare diseases. Zynerba is dedicated to improving the lives of patients through its research and development efforts in the field of cannabinoid-based therapies. With a focus on rigorous scientific methods and clinical data, Zynerba strives to deliver safe and effective treatments that address unmet medical needs. Through collaboration, integrity, and a commitment to improving patient outcomes, Zynerba Pharmaceuticals Inc aims to make a positive impact in the healthcare industry.

Zynerba Pharmaceuticals Inc is primarily present in the United States, with its headquarters located in Devon, Pennsylvania. As a pharmaceutical company specializing in developing cannabinoid therapies, Zynerba focuses on innovative treatments for various medical conditions. While primarily operating within the US market, Zynerba Pharmaceuticals Inc also explores global opportunities to expand its presence and reach. Through its dedication to research and development, Zynerba strives to provide effective and safe solutions for patients in need, aiming to improve the quality of life for individuals worldwide.

Zynerba Pharmaceuticals Inc, a leading pharmaceutical company, has achieved several significant milestones. With a focus on developing innovative therapeutics for rare and near-rare neuropsychiatric diseases, Zynerba has made noteworthy progress. They successfully completed Phase 2 clinical trials for their lead product candidate, Zygel, which aims to treat Fragile X syndrome, a genetic disorder. Moreover, Zynerba achieved positive results in Phase 3 trials for this candidate, demonstrating its potential efficacy. Additionally, the company obtained a Fast Track designation from the FDA for Zygel, which expedites the drug's development and review process. These milestones highlight Zynerba Pharmaceuticals' dedication to advancing novel treatments for critically underserved patient populations.

Zynerba Pharmaceuticals Inc. is a renowned pharmaceutical company that focuses on developing and commercializing innovative transdermal cannabinoid treatments. Founded in 2007, Zynerba has been dedicated to improving the lives of patients with various rare and near-rare neuropsychiatric disorders. The company is committed to utilizing its proprietary technology to develop high-quality and effective therapeutic solutions. Zynerba has made significant strides in the field, conducting clinical trials and collaborating with leading experts to advance the understanding and application of cannabinoids in medical treatments. With a strong emphasis on research and development, Zynerba Pharmaceuticals Inc. continues to pave the way in providing cutting-edge solutions for patients in need.

The main competitors of Zynerba Pharmaceuticals Inc in the market include GW Pharmaceuticals, Insys Therapeutics, and Axim Biotechnologies.

Zynerba Pharmaceuticals Inc primarily operates within the pharmaceutical industry.

The business model of Zynerba Pharmaceuticals Inc is focused on developing and commercializing innovative pharmaceutics derived from synthetic cannabinoid therapeutics. This entails researching, designing, and producing products with cannabinoids as their main active ingredients. As a specialty pharmaceutical company, Zynerba Pharmaceuticals strives to address unmet medical needs in various therapeutic areas, including neuropsychiatric, neurological, and pain disorders. By utilizing its proprietary transdermal delivery system, the company aims to provide convenient and effective treatment options for patients. With its commitment to advancing cannabinoid-based therapies, Zynerba Pharmaceuticals Inc aims to improve the lives of individuals suffering from debilitating conditions.

Az Zynerba Pharmaceuticals P/E mutatója -1,61.

Az Zynerba Pharmaceuticals KUV 4,83.

Az AlleAktien Minőségi Score Zynerba Pharmaceuticals esetében 3/10.

A várt Zynerba Pharmaceuticals forgalma 11,48 Mió. USD.

A(z) várt Zynerba Pharmaceuticals nyereség -34,52 Mió. USD.

Zynerba Pharmaceuticals Inc is an American company specializing in the development of cannabinoid therapies for various indications. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. Zynerba's business model includes various divisions, including research and development of medical compounds based on cannabinoids, production and marketing of corresponding drugs, and licensing its own patents and technologies to other companies. One key product of Zynerba is the transdermal cannabinoid gel ZYN002, which is currently being tested in various clinical trials for the treatment of conditions such as epilepsy, osteoarthritis, fibromyalgia, and fragile X syndrome. The gel is applied to the skin and is intended to have a long-lasting effect. Other research projects by Zynerba focus on the development of other cannabinoid-based compounds for the treatment of pain, inflammation, autoimmune diseases, and psychiatric disorders. To bring its products to the market, Zynerba collaborates with various partners, including contract manufacturing organizations, suppliers, clinical research facilities, and distributors. Currently, the company is primarily focused on its research and development activities and has not yet generated significant revenues. For the future, Zynerba plans to launch its products and expand its research activities. The company relies on close cooperation with regulatory authorities and other stakeholders to achieve successful approval of its drugs. Strengthening its patent portfolio and protecting intellectual property are also essential for Zynerba to secure its competitiveness. Overall, Zynerba Pharmaceuticals' business model presents a promising concept that builds on a promising medical technology (cannabinoid therapy) and has the potential to make a significant contribution to the treatment of various diseases.

A(z) Zynerba Pharmaceuticals évente alkalommal oszt ki 0 USD összegű osztalékot.

A Zynerba Pharmaceuticals esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Zynerba Pharmaceuticals ISIN kódja: US98986X1090.

A Zynerba Pharmaceuticals WKN-je A14XCV.

Az Zynerba Pharmaceuticals tőzsdei rövidítése ZYNE.

Az elmúlt 12 hónapban a(z) Zynerba Pharmaceuticals osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Zynerba Pharmaceuticals várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Zynerba Pharmaceuticals jelenlegi osztalékhozama .

A(z) Zynerba Pharmaceuticals negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Zynerba Pharmaceuticals az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Zynerba Pharmaceuticals a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Zynerba Pharmaceuticals által 2024. 09. 27.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 27.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 27. időpontban történt.

2023 évben a Zynerba Pharmaceuticals 0 USD összegű osztalékot fizetett ki.

Az Zynerba Pharmaceuticals osztalékait USD fizeti ki.